News | August 16, 2022
Kwality Pharmaceuticals Q1FY23 profit at Rs. 10.52 Cr
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.
Company appoints five new independent directors to reconstituted board
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
Subscribe To Our Newsletter & Stay Updated
